Back to User profile » Dr Fairooz Kabbinavar
Paper published by Dr Fairooz Kabbinavar:
Original Research
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer
Garon EB, Neidhart JD, Gabrail NY, de Oliveira MR, Balkissoon J, Kabbinavar F
OncoTargets and Therapy 2016, 9:7275-7283
Published Date: 30 November 2016